Precigen Announces First Patient Dosed in Phase 1 Study of PRGN-3005 UltraCAR-T™ in Patients with Advanced...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
Intrexon to Announce Second Quarter and First Half 2019 Financial Results on August 8th PR Newswire GERMANTOWN...
ActoBio Therapeutics™ Progresses AG019 to Next Stage of a Phase Ib/IIa Clinical Study for the Treatment of...
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed...
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.